x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

ReachMD CME

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:00:00

Emerging Therapies for Acute HAE: New Target, New...

ReachMD CME ·

2025/08/11

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35991/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term

en

00:00:00

Continuity in Care: Strategies for Managing Growth...

ReachMD CME ·

2025/08/05

CME credits: 0.50 Valid until: 05-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/continuity-in-care-strategies-for-managing-growth-hormone-deficiency-through-lifes-stages/35523/ Join Dr. Aristides Maniatis for this Patient-Clinician Connection, a case-based activity that explores the full spectrum of care in Growth Hormone Deficiency. Through real patient and caregiver dialogues, this program teaches clinicians how to identify early signs of GHD, make accurate diagnoses,

en

00:00:00

Chairperson’s Perspective: Optimizing Perioperative...

ReachMD CME ·

2025/08/01

CME credits: 0.25 Valid until: 01-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-optimizing-perioperative-therapy-in-early-stage-nsclc-a-multidisciplinary-approach/34985/ Perioperative immunotherapy has evolved into a novel therapeutic strategy for early-stage, resectable NSCLC, maximizing the efficacy of immunotherapy when the primary tumor is still present with a high neoantigen burden. Perioperative immunotherapy also allows the use of

en

00:00:00

Identifying a Key Cause of Hard to Control Diabetes

ReachMD CME ·

2025/08/01

CME credits: 1.00 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/identifying-a-key-cause-of-hard-to-control-diabetes/36543/ The diagnosis of hypercortisolism is often delayed or missed, especially in primary care settings, leading to detrimental consequences for patients, such as unnecessary morbidity and mortality. Recent data suggest that the prevalence of hypercortisolism is far higher than previously estimated. Clinicians need to be aware of optimal

en

00:00:00

Finding the Optimal Treatment for EGFR-mutated...

ReachMD CME ·

2025/07/31

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/finding-the-optimal-treatment-for-egfr-mutated-metastatic-nsclc/36150/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This

en

00:00:00

Applications of Emerging Data in Resectable NSCLC

ReachMD CME ·

2025/07/31

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/applications-of-emerging-data-in-resectable-nsclc/36147/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This

en

00:00:00

The Current Therapeutic Landscape in Unresectable...

ReachMD CME ·

2025/07/31

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-current-therapeutic-landscape-in-unresectable-stage-iii-nsclc/36148/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This

en

00:00:00

HER2-Driven Strategies in Metastatic NSCLC

ReachMD CME ·

2025/07/31

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/her2-driven-strategies-in-metastatic-nsclc/36151/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based

en

00:00:00

MET and Other Emerging Targets in Metastatic NSCLC

ReachMD CME ·

2025/07/31

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/met-and-other-emerging-targets-in-metastatic-nsclc/36152/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This

en

00:00:00

Updates in Limited-Stage Small Cell Lung Cancer...

ReachMD CME ·

2025/07/31

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/updates-in-limited-stage-small-cell-lung-cancer-ls-sclc/36145/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This

en

00:00:00

Strategies in EGFR-mutated Unresectable Stage III NSCLC

ReachMD CME ·

2025/07/31

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/strategies-in-egfr-mutated-unresectable-stage-iii-nsclc/36149/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This

en

00:00:00

Novel Therapies in Extensive-Stage Small Cell Lung...

ReachMD CME ·

2025/07/31

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/novel-therapies-in-extensive-stage-small-cell-lung-cancer-es-sclc/36146/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This

en

00:00:00

Emerging Therapeutic Developments in Non-Targetable...

ReachMD CME ·

2025/07/31

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapeutic-developments-in-non-targetable-metastatic-nsclc/36153/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This

en

00:00:00

Addressing CKM Mortality & Morbidity in Patients With...

ReachMD CME ·

2025/07/30

CME credits: 0.50 Valid until: 30-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/addressing-ckm-mortality-morbidity-in-patients-with-ckd-and-t2d-the-role-of-combined-ns-mra-sglt2i-therapy/29907/ This three-part panel series explores how emerging evidence from the CONFIDENCE trial is shaping the future of cardio-kidney-metabolic (CKM) care. In Chapter 1, the experts discuss the additive benefits and safety of combining a nonsteroidal MRA and an SGLT2 inhibitor. Chapter 2

en

00:00:00

ADCs Across the Spectrum of HER2 Expression in...

ReachMD CME ·

2025/07/29

CME credits: 0.25 Valid until: 29-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/adcs-across-the-spectrum-of-her2-expression-in-metastatic-breast-cancer/32202/ In this Virtual Case Clinic, explore three patient case examples with Dr. Mahtani as she demonstrates the application of the latest clinical evidence in HER2-positive, HER2-low, and HER2-ultralow metastatic breast cancer. By illustrating the use of antibody-drug conjugates in HER2-expressing disease, participants

en

00:00:00

Community Clinic: Translating Data Into Action ─...

ReachMD CME ·

2025/07/25

CME credits: 0.25 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/Community-Clinic-Translating-Data-Into-Action-Practical-Strategies-for-Optimizing-First-Line-RCC-Management/35774/ Our experts, Drs. Robert Motzer and Elizabeth Plimack, discuss first-line treatment strategies for advanced renal cell carcinoma in a community clinic setting. Drawing from pivotal clinical trials and guideline recommendations, they highlight how to personalize therapy based on

en

00:00:00

Optimize Outcomes in CKD & T2D: A Practical Approach...

ReachMD CME ·

2025/07/22

CME credits: 0.25 Valid until: 22-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimize-outcomes-in-ckd-t2d-a-practical-approach-to-initiating-and-monitoring-combination-ns-mra-sglt2i-therapy/29904/ The CONFIDENCE trial shows that combining an SGLT2 inhibitor with finerenone cuts albuminuria by more than 50% in patients with chronic kidney disease and type 2 diabetes. In this video, 2 nephrologists discuss how they apply these insights in clinical practice. A compelling

en

00:00:00

Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy

ReachMD CME ·

2025/07/17

CME credits: 0.50 Valid until: 17-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/contrasting-trop2-targeted-adcs-in-breast-cancer-therapy/33024/ This online chapterized CME activity features Drs. Kevin Kalinsky and Komal Jhaveri in a discussion on TROP2-targeted antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC). The faculty describe the therapeutic role of TROP2 as well as both approved and investigational ADCs that target TROP2. Clinical trial data on

en

00:00:00

Patient-Reported Outcome Measures (PROMs): Valuable...

ReachMD CME ·

2025/07/15

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-reported-outcome-measures-proms-valuable-insights-into-the-lived-experience-of-pah/33240/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs)

en

00:00:00

PROMs in Clinical Practice: Impacting Treatment...

ReachMD CME ·

2025/07/15

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-in-clinical-practice-impacting-treatment-decisions/33243/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making

en

226 results

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe